GES
0.011
83.3%
BLZ
0.002
-33.3%
ADN
0.02
66.7%
CZN
0.002
-33.3%
JAY
0.006
50%
PRX
0.002
-33.3%
M2R
0.003
50%
QXR
0.003
-25%
KLR
0.375
36.4%
WBE
0.003
-25%
ICR
0.023
35.3%
BYH
0.004
-20%
1TT
0.004
33.3%
RIM
0.012
-20%
PIL
0.004
33.3%
LKO
1.42
-18.9%
PEB
0.185
32.1%
NPM
0.022
-18.5%
FUN
0.125
30.2%
EXL
0.014
-17.6%
AVW
0.014
27.3%
OCN
0.072
-17.2%
ENX
0.024
26.3%
FNR
0.17
-17.1%
CAV
0.005
25%
TG1
0.03
-16.7%
RKB
0.005
25%
RTR
0.031
-16.2%
RML
0.06
25%
ALY
0.006
-14.3%
SIS
0.005
25%
BLU
0.006
-14.3%
WGR
0.14
21.7%
BNL
0.006
-14.3%
WNX
0.26
20.9%
LML
0.006
-14.3%
ERL
0.006
20%
VAR
0.006
-14.3%
MOH
0.006
20%
TLM
0.13
-13.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts